Northwest Biotherapeutics Highlights Cost Effectiveness of DCVax® in View of Recent Immunotherapy Pricing Concerns

BETHESDA, Md.--(BUSINESS WIRE)--Northwest Biotherapeutics (OTCBB: NWBO) reminded markets, in response to recent investor concerns about Dendreon’s Provenge immune therapy, that NWBT’s DCVax® immune therapies for a broad range of cancers (including prostate, brain, ovarian and others) hold the promise, based on available data to date, of being cost effective and priced below other immune therapies while still providing substantial profit margins for the Company and longer survival for patients.